Press release
Primary Biliary Cirrhosis - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies: Genfit, GentiBio Inc, GlaxoSmithKline, Hanmi Pharmaceut
Researcher experts consider it as an autoimmune disease in which the body turns against its own cells and the exact cause is unknown. Researchers believe this autoimmune response may be triggered by environmental and genetic factors.
As per Global Insight services' assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Primary Biliary Cirrhosis - pipeline landscape globally. Primary Biliary Cirrhosis Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31225
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Primary Biliary Cirrhosis treatment such as Elafibranor, Linerixibat, Setanaxib and others. Key players involved in the development of therapies to treat Primary Biliary Cirrhosis are Albireo, Calliditas Therapeutics AB, Genfit, GlaxoSmithKline, Merck Sharp & Dohme LLC and others. Six drugs are under late-stage Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2023 report provides an overview of the Primary Biliary Cirrhosis pipeline drugs. This report covers detailed insights on Primary Biliary Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Primary Biliary Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Read more about Primary Biliary Cirrhosis Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape/
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cirrhosis - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies: Genfit, GentiBio Inc, GlaxoSmithKline, Hanmi Pharmaceut here
News-ID: 2942220 • Views: …
More Releases from Global Insight Services
Governance Risk and Compliance (GRC) Platform Market to Expand From $53.5 Billio …
The Governance Risk And Compliance (GRC) Platform Market has emerged as a cornerstone for organizations striving to enhance accountability, streamline risk management, and meet growing regulatory demands. GRC platforms provide an integrated framework that enables companies to monitor compliance, manage risks, and ensure governance practices are aligned with industry standards. By combining risk assessment, audit management, compliance tracking, and policy enforcement, these platforms empower businesses to strengthen decision-making and safeguard…
Electronic Manufacturing Services (EMS) Market to Expand From $504.22 Billion in …
The Electronic Manufacturing Services (EMS) Market has become one of the most crucial sectors in the global technology-driven economy. EMS refers to the outsourcing of design, production, testing, and distribution of electronic components for original equipment manufacturers (OEMs). These services are indispensable across industries such as consumer electronics, automotive, telecommunications, and healthcare. In 2024, the EMS sector continues to play a pivotal role in improving efficiency, lowering production costs, and…
Catamaran Market Is Anticipated To Expand From $4.2 Billion In 2024 To $7.8 Bill …
Market Overview
The Catamaran Market is witnessing remarkable expansion, driven by the growing demand for recreational boating, marine tourism, and eco-friendly vessel options. Catamarans, recognized for their stability, spaciousness, and fuel efficiency, are increasingly preferred for leisure sailing, luxury tourism, and competitive racing. The market includes a wide range of offerings such as sailing catamarans, power catamarans, luxury yachts, and charter vessels, each catering to unique consumer preferences.
Innovations in sustainable…
Gear Motor Market to Expand From $24.5 Billion in 2024 to $39.8 Billion by 2034 …
The gear motor market is witnessing steady growth as industries worldwide increasingly depend on reliable and energy-efficient motion control systems. Gear motors, which combine a motor with a gearbox, play a vital role in converting electrical energy into mechanical torque with higher efficiency. These systems are essential across sectors like automotive, robotics, manufacturing, and renewable energy, offering enhanced precision, power transmission, and performance. The market is strongly supported by the…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
